[(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfamate



Compound IDCDAMM00149
Common name[(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfamate
IUPAC name[(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfamate
Molecular formulaC18H25NO4S

Experimental data

Retention time49.6
Adduct[M+H]+
Actual mz352.158
Theoretical mz352.158
Error0.56
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.7256

Identifiers and class information

Inchi keyYXYXCSOJKUAPJI-ZBRFXRBCSA-N
SmilesCC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)OS(=O)(=O)N
SuperclassLipids and lipid-like molecules
ClassSteroids and steroid derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)0
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)4
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)351.46
Computed dipole moment(dipole)3.944
Total solvent accessible surface area (SASA)591.046
Hydrophobic component of SASA (FOSA)303.093
Hydrophilic component of SASA (FISA)198.273
Pie component of the SASA (PISA)88.234
Weakly polar component of the SASA (WPSA)1.446
Total solvent accesible volume (volume)1061.81
Number of hydrogen bond donors (donorHB)3
Number of hydrogen bond acceptors (accptHB)6.7
Free energy of solvation of dipole (dip^2/V)0.0146481
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0196342
Globularity descriptor (glob)0.851614
Predicted polarizability in cubic angstroms (QPpolrz)34.614
Predicted hexadecane/gas partition coefficient (QPlogPC16)10.809
Predicted octanol/gas partition coefficient (QPlogPoct)19.644
Predicted water/gas partition coefficient (QPlogPw)13.202
Predicted octanol/water partition coefficient (QPlogPo/w)1.667
Predicted aqueous solubility (QPlogS)-4.011
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.927
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.354
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)130.519
Predicted brain/blood partition coefficient (QPlogBB)-1.497
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)55.772
Predicted skin permeability, log Kp (QPlogKp)-4.479
PM3 calculated ionization potential (IP(ev))9.338
PM3 calculated electron affinity (EA(eV))0.845
Number of likely metabolic reactions (#metab)3
Prediction of binding to human serum albumin (QPlogKhsa)0.036
Predicted qualitative human oral absorption (HumanOralAbsorption)3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)74.575
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)98.477
Number of nitrogen and oxygen atoms (#NandO)5
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
Q16790CA9Carbonic anhydrase IXT64567SEA
P00915CA1Carbonic anhydrase IT13201SEA
P00918CA2Carbonic anhydrase IIT20401SEA
P43166CA7Carbonic anhydrase VIIT37541SEA
P23280CA6Carbonic anhydrase VIT06569SEA
Q9ULX7CA14Carbonic anhydrase XIVT31992SEA
P42330AKR1C3Aldo-keto-reductase family 1 member C3T60857SEA
P10275ARAndrogen ReceptorT11211SEA
Q92731ESR2Estrogen receptor betaT80896SEA
P08185SERPINA6Corticosteroid binding globulinT88452SEA
P11511CYP19A1Cytochrome P450 19A1T13260SEA
P03372ESR1Estrogen receptor alphaT02506SEA
P33527ABCC1Multidrug resistance-associated protein 1T11288SEA
P11474ESRRAEstrogen-related receptor alphaT72841SEA
O95718ESRRBEstrogen-related receptor betaT42025SEA
P08842STSSteryl-sulfataseT33489SEA
Q9Y6L6SLCO1B1Solute carrier organic anion transporter family member 1B1T46814SEA
Q99527GPER1G-protein coupled estrogen receptor 1T65236SEA
O75751EMTHOrganic cation transporter 3T55948SEA
O15439ABCC4Multidrug resistance protein 4T39919SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T64567DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q16790CA9
T13201DI0166Glaucoma[ICD-11: 9C61]P00915CA1
T13201DI0372Seborrhoeic dermatitis[ICD-11: EA81]P00915CA1
T20401DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P00918CA2
T20401DI0137Essential hypertension[ICD-11: BA00]P00918CA2
T20401DI0166Glaucoma[ICD-11: 9C61]P00918CA2
T20401DI0175Heart failure[ICD-11: BD10-BD1Z]P00918CA2
T20401DI0214Insomnia[ICD-11: 7A00-7A0Z]P00918CA2
T20401DI0372Seborrhoeic dermatitis[ICD-11: EA81]P00918CA2
T06569DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P23280CA6
T06569DI0372Seborrhoeic dermatitis[ICD-11: EA81]P23280CA6
T31992DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q9ULX7CA14
T31992DI0204Inborn metabolism deficiency[ICD-11: 5C50-5C59]Q9ULX7CA14
T60857DI0145Female pelvic pain[ICD-11: GA34]P42330AKR1C3
T11211DI0005Acne vulgaris[ICD-11: ED80]P10275AR
T11211DI0012Acute myeloid leukaemia[ICD-11: 2A60]P10275AR
T11211DI0021Alcoholic liver disease[ICD-11: DB94]P10275AR
T11211DI0062Breast cancer[ICD-11: 2C60-2C6Y]P10275AR
T11211DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P10275AR
T11211DI0145Female pelvic pain[ICD-11: GA34]P10275AR
T11211DI0194Hypo-osmolality/hyponatraemia[ICD-11: 5C72]P10275AR
T11211DI0237Low bone mass disorder[ICD-11: FB83]P10275AR
T11211DI0247Mammary tumour[ICD-11: 2C60-2C6Z]P10275AR
T11211DI0346Prostate cancer[ICD-11: 2C82]P10275AR
T11211DI0401Testicular dysfunction[ICD-11: 5A81]P10275AR
T80896DI0062Breast cancer[ICD-11: 2C60-2C6Y]Q92731ESR2
T80896DI0108Cushing syndrome[ICD-11: 5A70]Q92731ESR2
T80896DI0254Menopausal disorder[ICD-11: GA30]Q92731ESR2
T80896DI0432Vasomotor/allergic rhinitis[ICD-11: CA08]Q92731ESR2
T88452DI0037Asthma[ICD-11: CA23]P08185SERPINA6
T88452DI0339Postoperative inflammation[ICD-11: 1A00-CA43]P08185SERPINA6
T88452DI0362Respiratory system disease[ICD-11: CB40-CB7Z]P08185SERPINA6
T13260DI0062Breast cancer[ICD-11: 2C60-2C6Y]P11511CYP19A1
T13260DI0108Cushing syndrome[ICD-11: 5A70]P11511CYP19A1
T02506DI0106COVID-19[ICD-11: 1D6Y]P03372ESR1
T11288DI0167Gout[ICD-11: FA25]P33527ABCC1
T72841DI0366Rheumatoid arthritis[ICD-11: FA20]P11474ESRRA
T33489DI0022Allergic/hypersensitivity disorder[ICD-11: 4A80-4A8Z]P08842STS
T65236DI0100Contraceptive management[ICD-11: QA21]Q99527GPER1

Copyright © 2025